Literature DB >> 1054621

Alteration of methotrexate uptake in human leukemia cells by other agents.

R A Bender, W A Bleyer, S A Frisby, V T Oliverio.   

Abstract

The uptake of methotrexate (MTX) and the effect of drugs known to either inhibit or enhance MTX transport in L1210 murine leukemia were studied in man using blast cells from patients with acute myelogenous leukemia in vitro. MTX uptake was found to proceed slowly, requiring at least 160 min for cells to reach a "steady state" when extracellular MTX concentrations were 1 muM. Efflux of MTX from preloaded cells required 80 to 120 min and the nonexchangeable or tightly bound fraction was 40% of the total intracellular drug. Utilizing doses that are estimates of achievable peak blood levels following single i.v. injection, cephalothin (21 mug/ml) and hydrocortisone (20 mug/ml) inhibited net MTX accumulation by 20 and 28%, respectively. Vincristine sulfate at 8.3 and 0.083 mug/ml enhanced MTX uptake by 54 and 33%, respectively, by inhibiting MTX efflux, thus increasing the level of intracellular drug in excess of the tightly bound fraction. The potential clinical implications of using MTX in combination with the aforementioned drugs for cancer chemotherapy are discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1054621

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  [High-dose methotrexate therapy in osteogenic sarcoma: plasma pharmakokinetics to predict toxicity (author's transl)].

Authors:  G E Janka; H Wiesner; F Bidlingmaier; R J Haas
Journal:  Klin Wochenschr       Date:  1979-04-17

Review 2.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

3.  Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia.

Authors:  P J Kearney; P A Light; A Preece; M G Mott
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  Methotrexate in erythrocytes of patients with psoriasis.

Authors:  H Schrøder; E K Foged
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Collateral sensitivity of a methotrexate-resistant L1210 cell line to the vinca alkaloids.

Authors:  D G Poppitt; A T McGown; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

6.  Effects of hyaluronidase on doxorubicin penetration into squamous carcinoma multicellular tumor spheroids and its cell lethality.

Authors:  N Kohno; T Ohnuma; P Truog
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

7.  Interactions of vinblastine and vincristine with methotrexate transport in isolated rat hepatocytes.

Authors:  E Smeland; R M Bremnes; A Bessesen; R Jaeger; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3.

Authors:  Chenrong Huang; Fan Xia; Ling Xue; Linsheng Liu; Yicong Bian; Zhengming Jin; Liyan Miao
Journal:  Cancer Chemother Pharmacol       Date:  2019-11-05       Impact factor: 3.333

9.  In vitro correlates of clinical response to methotrexate in actue leukaemia and Burkitt's lymphoma.

Authors:  R A Bender; W A Bleyer; J C Drake; J L Ziegler
Journal:  Br J Cancer       Date:  1976-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.